Gastrointestinal Disease Tied to High Physical, Financial Burden
By Lori Solomon HealthDay Reporter
FRIDAY, April 18, 2025 -- Gastrointestinal (GI) diseases are responsible for a considerable and growing burden of health care use and costs within the United States, according to a study recently published online in Gastroenterology.
Anne F. Peery, M.D., from the University of North Carolina at Chapel Hill, and colleagues estimated the burden and costs associated with GI diseases in the United States.
The researchers found that in 2021, GI health care expenditures totaled $111.8 billion. An estimated 14.5 million emergency department visits and 2.9 million hospital admissions resulted from a GI diagnosis or symptom. One in six U.S. adults reported having one or more frequent GI symptoms in the past three months. Diagnoses of 315,065 new GI cancers were made, and GI diseases caused 281,413 deaths. An estimated 23.5 million GI endoscopies were performed in 2022. The National Institutes of Health supported $3.6 billion for GI research in 2023, representing 7.4 percent of its budget.
"Our report captures the remarkable and changing burden of GI diseases in the United States," the authors write. "There is an ongoing need to support GI sciences, which offers the promise of preventing or treating these highly prevalent and morbid conditions. There is also clearly an extraordinary demand for specialized teams that practice GI medicine and provide the daily support and care for patients with GI diseases."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Prevalence of Disorders of Gut-Brain Interaction Increased After Pandemic
TUESDAY, Aug. 5, 2025 -- The prevalence of disorders of the gut-brain interaction (DGBI) increased from before to after the COVID-19 pandemic, according to a study published...
Guselkumab Efficacious for Moderately to Severely Active Crohn Disease in Adults
THURSDAY, July 24, 2025 -- Intravenous induction followed by subcutaneous maintenance therapy with guselkumab is efficacious for adults with moderately to severely active Crohn...
Digital Model Based on Noninvasive Factors Shows Accuracy for Identifying IBD in Children
TUESDAY, July 22, 2025 -- A model based on noninvasive tests shows high accuracy as a digital tool for the rapid identification of children with inflammatory bowel disease (IBD)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.